A novel immune signature predicts immunotherapy responsiveness and reveals the landscape of the tumor immune microenvironment in head and neck squamous cell carcinoma

Background: Immune-checkpoint blockade (ICB) has been routinely implemented to treat head and neck squamous cell carcinoma (HNSCC) patients. However, only a few patients benefit from immune checkpoint inhibitor (ICI) therapies. Methods: In this study, we used a combined cohort (including the GSE4161...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qiwei, Zhao, Yinan, Wang, Fang, Tan, Guolin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691887/
https://www.ncbi.nlm.nih.gov/pubmed/36437964
http://dx.doi.org/10.3389/fgene.2022.1051051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691887/
https://www.ncbi.nlm.nih.gov/pubmed/36437964
http://dx.doi.org/10.3389/fgene.2022.1051051

Ejemplares similares